Articles related to NEOADJUVANT TREATMENT
Pembrolizumab for Early Triple-Negative Breast Cancer
Early triple-negative breast cancer patients who received pembrolizumab along with neoadjuvant chemotherapy had a significantly higher rate of pathological complete responses than those who received placebo along with neoadjuvant chemotherapy.
Oncology, Medical November 28th 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Neoadjuvant nivolumab plus chemotherapy improved event-free survival and increased the proportion of patients who had a pathological complete response in patients with resectable NSCLC compared to chemotherapy alone. Nivolumab was added to neoadjuvant chemotherapy, but neither the incidence of side effects nor the viability of surgery was affected.
Oncology, Medical November 7th 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Neoadjuvant cemiplimab was administered to a total of 79 individuals. Upon independent review, a pathological complete response (51 percent; 95% confidence interval [CI], 39 to 62) was noted in 40 patients, and a pathological substantial response (13 percent; 95% CI, 6 to 22) was noted in 10 patients. These outcomes matched the abnormal reactions identified during the investigator’s examination. Fifty-four (54) patients (68%; 95% CI, 57 to 78) had an objective response on imaging, and 69 individuals (87%) experienced adverse events of any grade that happened throughout the course of the study, regardless of whether they were linked to the study treatment. Fourteen (14) participants (18%) experienced adverse events of grade 3 or higher during the research period.
Dermatology October 31st 2022
“Striking” Colon Cancer Data Spur Mid-Presentation Ovation at ESMO
With two cycles of neoadjuvant immunotherapy, nearly every patient with mismatch repair-deficient (dMMR) colon cancer in the NICHE-2 trial achieved a pathologic response. At a median follow-up of 13.1 months, the disease-free survival (DFS) rate was 100% vs. an expected rate for this patient population of 15%.
Oncology, Medical September 12th 2022
ICIs Appear Safer Than TKIs for Advanced Hepatocellular Carcinoma
The meta-analysis included data from nearly 13,000 patients across 30 published trials. Grade 3 or 4 AEs occurred in nearly 70% of patents receiving TKIs compared with 37% for those receiving ICIs.
Oncology, Medical August 16th 2022
Neodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLC
At 12 months, nivolumab plus chemotherapy yielded a PFS of 89.3% versus 60.7% forchemotherapy alone and an OS of 98.2% compared with 82.1%, respectively. Thecombination improved median PFS by 52% compared with chemotherapy alone at amedian follow-up of 26.1 months. (See also NADIM II and IMpower010 Provide Support for Neoadjuvant and Adjuvant Immunotherapy in Lung Cancer)
Oncology, Medical August 15th 2022